The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
- 1 August 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (10) , 1921-1929
Abstract
OBJECTIVE In people with type 2 diabetes, sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risk and progression of diabetic kidney disease. Our aim was to determine whether sotagliflozin (SOTA), a dual SGLT1i and SGLT2i, had favorable effects on clinical biomarkers suggestive of kidney protection in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS In this 52-week pooled analysis, 1,575 adults enrolled in the inTandem1 and inTandem2 trials were randomized to SOTA 200 mg, 400 mg, or placebo in addition to optimized insulin therapy. Changes in cardiorenal biomarkers were assessed. RESULTS At 52 weeks, in response to SOTA 200 and 400 mg, the placebo-corrected least squares mean change from baseline in estimated glomerular filtration rate was −2.0 mL/min/1.73 m2 (P = 0.010) and −0.5 mL/min/1.73 m2 (P = 0.52), respectively. Systolic blood pressure difference was −2.9 and −3.6 mmHg (P < 0.0001 for both); diastolic blood pressure changed by −1.4 (P = 0.0033) and −1.6 mmHg (P = 0.0008). In participants with baseline urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g, UACR decreased by 23.7% (P = 0.054) and 18.3% (P = 0.18) for SOTA 200 and SOTA 400 mg, respectively, versus placebo. Increases in serum albumin and hematocrit and reductions in uric acid were observed throughout 52 weeks with both SOTA doses. CONCLUSIONS SOTA was associated with short- and long-term renal hemodynamic changes, which were similar to those seen with SGLT2i in type 2 diabetes. Further investigation around cardiorenal effects of SOTA in people with type 1 diabetes is justified.Keywords
Funding Information
- Lexicon Pharmaceuticals, Inc.
- Sanofi
This publication has 43 references indexed in Scilit:
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept TrialDiabetes Care, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol StudyCurrent Diabetes Reports, 2013
- LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal GlucoseThe Journal of Pharmacology and Experimental Therapeutics, 2013
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled TrialClinical Pharmacology & Therapeutics, 2012
- GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat dietAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications StudyDiabetologia, 2010
- The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 DiabetesDiabetes, 2009
- Glomerulotubular Balance, Tubuloglomerular Feedback, and Salt HomeostasisJournal of the American Society of Nephrology, 2008
- Molecular Characterization of an Arachidonic Acid Epoxygenase in Rat Brain AstrocytesStroke, 1996